ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.
Nutriband hat von United States Patent and Trademark Office (USPTO) eine Notice of Publication für Marken des kommerziellen Produktnamens seines Leitprodukts, eines missbrauchsresistenten fentanyltransdermalen Systems, erhalten. Sobald die Marke zugelassen ist, plant Nutriband, seinen kommerziellen weltweiten Produktnamen der FDA und anderen internationalen Zulassungsbehörden zur Genehmigung vo...
Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Acti...
ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company's AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.
Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.